The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study.


Journal

Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449

Informations de publication

Date de publication:
Apr 2021
Historique:
revised: 23 12 2020
received: 23 11 2020
accepted: 12 01 2021
pubmed: 17 1 2021
medline: 6 11 2021
entrez: 16 1 2021
Statut: ppublish

Résumé

The General European Official Medicines Control Laboratory (OMCL) Network (GEON), co-ordinated by the European Directorate for the Quality of Medicines & HealthCare (EDQM), regularly organises market surveillance studies on specific categories of suspected illegal or illegally traded products. These studies are generally based on a combination of retrospective and prospective data collection over a defined period of time. This paper reports the results of the most recent study in this context with the focus on health products containing non-Anatomical Therapeutic Chemical-International Nonproprietary Name (ATC-INN) molecules. In total 1104 cases were reported by 16 countries for the period between January 2017 and the end of September 2019. The vast majority of these samples (83%) were collected from the illegal market, while only 3% originated from a legal source. For the rest of the samples, categorisation was not possible. Moreover, 69% of all the reported samples were presented as medicines, including sexual performance enhancers, sports performance enhancers, physical performance enhancers and cognitive enhancers or nootropic molecules that act on the central nervous system (CNS). Although the popularity of anabolics, PDE-5 inhibitors and CNS drugs in illegal products has already been reported, the study showed some new trends and challenges. Indeed, 11% of the samples contained molecules of biological origin, that is, research peptides, representing the second most reported category in this study. Furthermore, the study also clearly shows the increasing popularity of Selective Androgen Receptor Modulators and nootropics, two categories that need attention and should be further monitored.

Identifiants

pubmed: 33453144
doi: 10.1002/dta.3001
doi:

Substances chimiques

Illicit Drugs 0
Performance-Enhancing Substances 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

833-840

Informations de copyright

© 2021 John Wiley & Sons, Ltd.

Références

https://www.edqm.eu/en/general-european-omcl-network-geon (last accessed 28/10/2020).
European Parliament, European Council. European directive 2004/28/CEE. Off J Eur Union. 2004;L136:58-84.
https://www.edqm.eu/en/edqms-response-nitrosamine-contamination (last accessed 28/10/2020).
World Health Organization, Substandard and falsified medical products, (2018). http://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products (last accessed 28/10/2020).
International Medical Products Anti-Counterfeiting Taskforce (IMPACT). Counterfeit drugs kill. 21-5-2014. Ref Type: Online Source; 2008.
Venhuis BF, Keizers PHJ, Klausmann R, Hegger I. Operation resistance: a snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. Drug Test Anal. 2016;8(3-4):398-401. https://doi.org/10.1002/dta.1888
Tie Y, Vanhee C, Deconinck E, Adams E. Development and validation of chromatographic methods for screening and subsequent quantification of suspected illegal antimicrobial drugs encountered on the Belgian market. Talanta. 2019;194:876-887. https://doi.org/10.1016/j.talanta.2018.10.078
https://www.edqm.eu/en/testing-falsified-illegal-medicines (last accessed 28/10/2020).
https://www.edqm.eu/medias/fichiers/study_report_on_slimming_dietary_supplements.pdf (last accessed 28/10/2020).
https://www.edqm.eu/sites/default/files/mssip002-omcl_summary_report.pdf (last accessed 28/10/2020).
https://www.edqm.eu/sites/default/files/omcl-market-surveillance-summary-report-mssip03-illegal-anabolic-steroids-march2018.pdf (last accessed 28/10/2020).
https://www.edqm.eu/sites/default/files/medias/fichiers/OMCL/study_report_on_medicines_in_disguise.pdf (last accessed 28/10/2020).
Biesterbos JWH, Sijm DTHM, van Dam R, Mol HGJ. A health risk for consumers: the presence of adulterated food supplements in the Netherlands. Food Addit Contam Part a Chem Anal Control Expo Risk Assess. 2019;36(9):1273-1288. https://doi.org/10.1080/19440049.2019.1633020
Manna L, Gaudiano MC, Bartolomei M, et al. A special case of medicine in disguise: Tattoo inks containing anaesthetics. Talanta. 2019;198:337-343. https://doi.org/10.1016/j.talanta.2019.02.033
Yeo M, Park Y, Lee H, et al. New metabolites of hongdenafil, homosildenafil and hydroxyhomosildenafil. J Pharm Biomed Anal. 2018;149:586-590. https://doi.org/10.1016/j.jpba.2017.11.057
Venhuis BJ, de Kaste D. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J Pharm Biomed Anal. 2012;69:196-208. https://doi.org/10.1016/j.jpba.2012.02.014
Breindahl T, Evans-Brown M, Hindersson P, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the internet. Drug Test Anal. 2015;7(2):164-172. https://doi.org/10.1002/dta.1655
Janvier S, De Spiegeleer B, Vanhee C, Deconinck E. Falsification of biotechnology drugs: current dangers and/or future disasters? J Pharm Biomed Anal. 2018;161:175-191. https://doi.org/10.1016/j.jpba.2018.08.037
Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal. 2020;12(3):371-381. https://doi.org/10.1002/dta.2717
Vanhee C, Tuenter E, Kamugisha A, et al. Identification and quantification methodology for the analysis of suspected illegal dietary supplements: reference standard or no reference standard, that the question. J Forensic Toxicol Pharmacol. 2018;7:1-7. https://doi.org/10.4172/2325-9841
Burmeister MA, Fincher TK, Graham WH. Recreational use of selective androgen receptor modulators. US Pharm. 2020;45:15-18.
General European OMCL Network (GEON). General document PA/PH/OMCL (06) 81 R10 (2019). An “aide-mémoire” for the testing of suspected illegally traded and falsified medicines. EDQM, Council of Europe, Strasbourg, France.
The pharmaceutical security institute. (2019). https://www.psi-inc.org/therapeutic-categories (last accessed 28/10/2020).
Janvier S, Cheyns K, Canfyn M, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. https://doi.org/10.1016/j.talanta.2018.06.023
Thevis M, Schänzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2018;464:34-45. https://doi.org/10.1016/j.mce.2017.01.040
Wilms W, Woźniak-Karczewska M, Corvini PF, Chrzanowski Ł. Nootropic drugs: Methylphenidate, modafinil and piracetam-population use trends, occurrence in the environment, ecotoxicity and removal methods-a review. Chemosphere. 2019;233:771-785. https://doi.org/10.1016/j.chemosphere.2019.06.016

Auteurs

Eric Deconinck (E)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, Brussels, Belgium.

Celine Vanhee (C)

Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, Brussels, Belgium.

Peter Keizers (P)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Department of Product Composition, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Pauline Guinot (P)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Laboratory Controls Division, French National Agency for Medicines and Health Products Safety, Vendargues, France.

Albena Mihailova (A)

Laboratory, Division Reliable Supply, Norwegian Medicines Agency, Oslo, Norway.

Per Vidar Syversen (PV)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Laboratory, Division Reliable Supply, Norwegian Medicines Agency, Oslo, Norway.

Graziella Li-Ship (G)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Inspections, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, UK.

Steven Young (S)

Inspections, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, UK.

Agata Blazewicz (A)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Falsified Medicines and medical Devices Department, National Medicines Institute, Warsaw, Poland.

Magdalena Poplawska (M)

Falsified Medicines and medical Devices Department, National Medicines Institute, Warsaw, Poland.

Josephine Loasby Al-Sayed (JL)

Medicines Control and Inspection Division, Danish Medicines Agency, Copenhagen, Denmark.

Lone Stengelshøj Olsen (L)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Medicines Control and Inspection Division, Danish Medicines Agency, Copenhagen, Denmark.

Oliver El-Atma (O)

Medicinal Products, Chemical and Veterinary Investigation Office, Karlsruhe, Germany.

Roman Leist (R)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
OMCL, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.

Karl-Henrik Jönsson (KH)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Laboratory Department, Swedish Medical Products Agency, Uppsala, Sweden.

Maria Afxentiou (M)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Forensic Chemistry and Toxicology Laboratory, State General Laboratory, Nicosia, Cyprus.

M Mendoza Barrios (MM)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Chemical and Pharmaceutical Division, Medicines for Human Use Department, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain.

I Dorronsoro Diaz (ID)

Chemical and Pharmaceutical Division, Medicines for Human Use Department, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain.

Marina Zemser (M)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Institute of Standardization and Control of Pharmaceuticals, Ministry of Health Israel, Jerusalem, Israel.

Alla Kozokin (A)

Institute of Standardization and Control of Pharmaceuticals, Ministry of Health Israel, Jerusalem, Israel.

Andreas Hackl (A)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Institute Assessment & Analytics, Analytics of chemical-pharmaceutical Medicinal Products, AGES-Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH, Wien, Austria.

Maria-Jao Portela (MJ)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.
Direção de Comprovação da Qualidade, INFARMED-Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., Lisbon, Portugal.

Nico Beerbaum (N)

Institut für Lebensmittel, Arzneimittel, Tierseuchen und Umwelt, Landeslabor Berlin-Brandenburg, Berlin, Germany.

Marie Bertrand (M)

OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH